The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

Abstract : In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-01798193
Contributor : Apemac Ul <>
Submitted on : Wednesday, May 23, 2018 - 11:44:24 AM
Last modification on : Thursday, April 11, 2019 - 4:02:23 PM

Identifiers

Citation

Thierry Conroy, Céline Gavoille, Emmanuelle Samalin, Marc Ychou, Michel Ducreux. The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. Current Oncology Reports, Current Medicine Group, 2013, 15 (2), pp.182 - 189. ⟨10.1007/s11912-012-0290-4⟩. ⟨hal-01798193⟩

Share

Metrics

Record views

55